VOR logo

Vor Biopharma Inc

VOR

Build a strategy around VOR

Accountable AI Logo

Vor Biopharma Inc AI Insights

Informational only. Not investment advice.
As of 2025-12-11

Snapshot

  • Zero revenue with -367M TTM operating loss; 160M cash remaining covers ~13 months at current -144M annual burn rate[Cash and Equivalents]
  • Negative equity of -2.2B driven by -790M investment loss (TTM) - balance sheet technically insolvent[Common Stockholders Equity]
  • R&D spend of 328M TTM is 8.7x industry median (38M) - heavy clinical investment with no revenue offset[Research and Development]

Watch Triggers

  • Cash and Equivalents: Falls below 100MWould signal <9 months runway, forcing emergency financing at distressed terms
  • Issuance of Capital Stock: Exceeds 50M quarterlyHeavy dilution signal; current 20M TTM pace insufficient for survival
  • Total Revenue: Any positive revenue recognitionWould indicate partnership deal or milestone payment - thesis-changing event

Bull Case

Pre-revenue biotech with 328M R&D investment; clinical success could transform valuation from 81M market cap

Research and DevelopmentMarket Cap

Minimal debt (3M) and low capex (<1M TTM) means cash funds R&D directly, not servicing obligations

Total DebtCapital Expenditure

Bear Case

Negative equity (-2.2B) with liabilities of 2.4B creates existential balance sheet risk; P/B ratio meaningless at -0.04

Total EquityTotal Liabilities as Reported

13-month cash runway at current burn requires imminent dilution; 6.7M shares could expand significantly

Cash and EquivalentsFree Cash FlowShares Outstanding

Bull vs Bear Balance

AI-generated sentiment analysis based on fundamental metrics and market conditions.

BearBull
25%

Leverage VOR's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.

Take Me to The Editor

Forward Thesis

Cash runway exhaustion likely within 12-18 months without dilutive financing or partnership

3-12mhigh
  • 160M cash vs 144M annual burn
  • Zero revenue generation
  • 20M equity issuance TTM insufficient
FCF TTM: -145MCash: 160MIssuance of Capital Stock: 20M TTM

Valuation Context

Caveats

Data Partners
Morningstar Logo

Fundamental company data provided by Morningstar, updated daily.

Accountable Finance, Inc. Disclaimer
accountable.finance is not operated by a broker or a dealer. Under no circumstances does any information posted on accountable.finance represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. In no event shall accountable.finance be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on accountable.finance, or relating to the use of, or inability to use, accountable.finance or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. Stock quotes and fundamental company data provided by Morningstar, updated daily.

Accountable Logo
© 2026 Accountable Finance, Inc. All rights reserved.